Patients & Volunteers Information for those interested or currently participating in a clinical trial
	Research Sponsors Why you should choose Aurora for your clinical trials
	Investigators & Coordinators Learn more about our services
	Research Matters Quarterly newsletter about research at Aurora
	Links Learn more about clinical research
	Contact us Contact the Clinical Research department
	Return home Return to the Clinical Research home page

Select from the search options to widen or narrow the search results.

Metastatic Melanoma Study

 Study Purpose:   This study takes advantage of the body's natural immune system

 to produce Tumor Infiltrating Lymphocytes (TIL) in a cellular therapy lab.  

TIL will then be given back to the patient in combination with chemotherapy and growth factor (Interleukin-2).

The study will determine whether this combination of drugs and cells cause melanoma tumors to "shrink" and whether it can be given safely to patients.

Participants must: 

• Have melanama that has spread to other areas of the body (metastasized)
• Have had prior high dose Interleukin-2 therapy
• Be 18 years of age or older
• Able to perform activities of daily living

Additional eligibillity criteria must be met at time of screening

For more information, please contact:

 Cathy Schott, RN  

Phone: 414-649-5971 

cathy.schott@aurora.org

or

 Jeannie Dettman, RN 

Phone: 414-649-7584

jeannie.dettman@aurora.org

John P. Hanson, MD, Principal Investigator

Jonathan Treisman, MD, Sub-Investigator

Clinical trial location(s)

[ previous page ]

Copyright Aurora Health Care, a not-for-profit health care provider serving Wisconsin.
3000 W. Montana St., Milwaukee, WI 53215, (414) 647-3000
Disclaimer | Privacy notice | Contact us
.